Clinical Trial Update: A Feasibility and Safety Study of CD38 CAR-T Cell Immunotherapy for Relapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T Adoptive Cellular Immunotherapy [Phase 1, Phase 2]

View source ↗

Summary

Feasibility and safety study of CD38 CAR-T cell therapy for relapsed B-cell acute lymphoblastic leukemia following CD19 CAR-T, conducted in Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• CD38 CAR-T cell immunotherapy (CD38 CAR-T)

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: Relapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T ACI | Phase 1, Phase 2 | Status: UNKNOWN